Stocks
Allogene Therapeutics (ALLO) EBITDA US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -169.7 | -321.2 | -313.1 | -243.3 | -194.6 | -171.0 | ||
| Changes by years, y/y, % | -32% | +89% | -3% | -22% | -20% | -5.0% | |||
Allogene Therapeutics. EBITDA US GAAP, bln rub
Allogene Therapeutics. EBITDA US GAAP, changes, %
Allogene Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Allogene Therapeutics (ALLO) EBITDA US GAAP (quarter values) |
||||||||
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | LTM ? | |||
| EBITDA, bln rub | ? | -56.5 | -47.6 | -38.0 | -39.3 | -46.1 | -171.0 | |
| Changes by years, y/y, % | -8% | -24% | -40% | -30% | -18% | |||
| Changes by quarters, q/q, % | +1% | -16% | -20% | +4% | +17% | |||
